Performance of dedicated breast positron emission tomography in the detection of small and low-grade breast cancer.
Breast cancer
Dedicated breast PET
Positron emission tomography
Sensitivity
Whole body PET
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
31
07
2020
accepted:
31
12
2020
pubmed:
24
1
2021
medline:
24
6
2021
entrez:
23
1
2021
Statut:
ppublish
Résumé
This study compares the sensitivity of dedicated breast positron emission tomography (DbPET) and whole body positron emission tomography (WBPET) in detecting invasive breast cancer based on tumor size and biology. Further, we explored the relationship between maximum standardized uptake value (SUVmax) of DbPET and biological features of the tumor. A total of 639 invasive breast cancer lesions subjected to both DbPET and WBPET before surgery, between January 2016 and May 2019, were included in the study. The sensitivity of DbPET and WBPET in detection and the biology of the tumor according to the clinicopathological features were retrospectively evaluated. The overall sensitivity of DbPET was higher than that of WBPET (91.4% vs. 80.3%, p < 0.001). Subcentimetric tumors were significant (80.9% vs. 54.3%, p < 0.001). Regardless of the nuclear grade, DbPET could detect more lesions than WBPET. The SUVmax was positively correlated with tumor size (R = 0.395, p < 0.001) and the nuclear grade (p < 0.001). Luminal A-like breast cancer had significantly lower SUVmax values than the other subtypes (p < 0.001). DbPET is superior to WBPET in the detection of subcentimetric, low-grade breast cancers. Further, by using SUVmax, DbPET can distinguish luminal A-like breast cancer from the other subtypes.
Identifiants
pubmed: 33484374
doi: 10.1007/s10549-020-06088-1
pii: 10.1007/s10549-020-06088-1
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-133Références
Welch HG, Prorok PC, O’Malley AJ, Kramer BS (2016) Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375:1438–1447
doi: 10.1056/NEJMoa1600249
Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L (2016) Screening for breast cancer: a systematic review to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med 164:244–255
doi: 10.7326/M15-0969
Ichizawa N, Fukutomi T, Iwamoto E, Akashi-Tanaka S (2002) Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification. Jpn J Clin Oncol 32:108–109
doi: 10.1093/jjco/hyf025
Escalona S, Blasco JA, Reza MM, Andradas E, Gómez N (2010) A systematic review of FDG-PET in breast cancer. Med Oncol 27:114–129
doi: 10.1007/s12032-009-9182-3
Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer-usefulness for malignant grade of triple-negative breast cancer. Breast 22:958–963
doi: 10.1016/j.breast.2013.05.003
Sasada S, Masumoto N, Suzuki E, Sueoka S, Goda N, Kajitani K et al (2019) Prediction of biological characteristics of breast cancer using dual-phase FDG PET/CT. Eur J Nucl Med Mol Imaging 46:831–837
doi: 10.1007/s00259-019-4259-5
Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M (2013) Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat 141:269–275
doi: 10.1007/s10549-013-2687-7
Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N et al (2015) Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat 150:209–217
doi: 10.1007/s10549-015-3303-9
Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A (2006) Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98:267–274
doi: 10.1007/s10549-006-9159-2
Kanumuri P, Hayse B, Killelea BK, Chagpar AB, Horowitz NR, Lannin DR (2015) Characteristics of multifocal and multicentric breast cancers. Ann Surg Oncol 22:2475–2482
doi: 10.1245/s10434-015-4430-6
Wolters R, Wöckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R et al (2013) Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat 142:579–590
doi: 10.1007/s10549-013-2772-y
Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchhholz TA et al (2012) Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23:3063–3069
doi: 10.1093/annonc/mds136
Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA (2009) Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 117:365–370
doi: 10.1007/s10549-008-0265-1
Ozturk A, Alco G, Sarsenov D, Ilgun S, Ordu C, Koksal U et al (2018) Synchronous and metachronous bilateral breast cancer: a long-term experience. J Boun 23:1591–1600
Michowitz M, Noy S, Lazebnik N, Aladjem D (1985) Bilateral breast cancer. J Surg Oncol 30:109–112
doi: 10.1002/jso.2930300210
Gogas J, Markopoulos C, Skandalakis P, Gogas H (1993) Bilateral breast cancer. Am Surg 59:733–735
pubmed: 8239195
Tafra L, Cheng Z, Uddo J, Lobrano MB, Stein W, Berg WA et al (2005) Pilot clinical trial of 18F-fluorodeoxyglucose positron-emission mammography in the surgical management of breast cancer. Am J Surg 190:628–632
doi: 10.1016/j.amjsurg.2005.06.029
Yamamoto Y, Ozawa Y, Kubouchi K, Nakamura S, Nakajima Y, Inoue T (2015) Comparative analysis of imaging sensitivity of positron emission mammography and whole-body PET in relation to tumor size. Clin Nucl Med 40:21–25
doi: 10.1097/RLU.0000000000000617
Berg WA, Weinberg IN, Narayanan D, Lobrano ME, Ross E, Amodei L et al (2006) High-resolution fluorodeoxyglucose positron emission tomography with compression (“positron emission mammography”) is highly accurate in depicting primary breast cancer. Breast J 12:309–323
doi: 10.1111/j.1075-122X.2006.00269.x
Nishimatsu K, Nakamoto Y, Miyake K, Ishimori T, Kanao S, Toi M et al (2017) Higher breast cancer conspicuity on dbPET compared to WB-PET/CT. Eur J Radiol 90:138–145
doi: 10.1016/j.ejrad.2017.02.046
Brierley JD, Gospodararowicz MK, Wittekind C (2016) Union for International Cancer Control (UICC) TNM classification of malignant tumours, 8th Edition. Oxford
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
doi: 10.1200/JCO.2009.25.6529
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
doi: 10.1200/JCO.2013.50.9984
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M et al (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26:1533–1546
doi: 10.1093/annonc/mdv221
Kumar R, Alavi A (2004) Fluorodeoxyglucose-PET in the management of breast cancer. Radiol Clin North Am 42:1113–1122
doi: 10.1016/j.rcl.2004.08.005
Hosono M, Saga T, Ito K, Kumita S, Sasaki M, Senda M et al (2014) Clinical practice guideline for dedicated breast PET. Ann Nucl Med 28:597–602
doi: 10.1007/s12149-014-0857-2
Sasada S, Masumoto N, Goda N, Kajitani K, Emi A, Kadoya T et al (2018) Which type of breast cancers is undetectable on ring-type dedicated breast PET? Clin Imaging 51:186–191
doi: 10.1016/j.clinimag.2018.05.010
Sasada S, Masumoto N, Kimura Y, Emi A, Kadoya T, Okada M (2020) Classification of abnormal findings on ring-type dedicated breast PET for the detection of breast cancer. Anticancer Res 40:3491–3497
doi: 10.21873/anticanres.14336
Duffy SW, Tabár L, Yen AM, Dean PB, Smith RA, Jonsson H et al (2020) Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. Cancer 126:2971–2979
doi: 10.1002/cncr.32859
Moscoso A, Ruibal Á, Domínguez-Prado I, Fernández-Ferreiro A, Herranz M, Albaina L et al (2018) Texture analysis of high-resolution dedicated breast 18 F-FDG PET images correlates with immunohistochemical factors and subtype of breast cancer. Eur J Nucl Med Mol Imaging 45:196–206
doi: 10.1007/s00259-017-3830-1